LeonaBio, Inc. (LONA)
NASDAQ: LONA · Real-Time Price · USD
5.56
+0.03 (0.54%)
At close: Feb 20, 2026, 4:00 PM EST
5.67
+0.11 (1.98%)
After-hours: Feb 20, 2026, 6:45 PM EST
LeonaBio Employees
LeonaBio had 26 employees as of December 31, 2024. The number of employees decreased by 41 or -61.19% compared to the previous year.
Employees
26
Change (1Y)
-41
Growth (1Y)
-61.19%
Revenue / Employee
n/a
Profits / Employee
-$1,450,885
Market Cap
51.91M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 26 | -41 | -61.19% | 26 | 0 |
| Dec 31, 2023 | 67 | 3 | 4.69% | 65 | 2 |
| Dec 31, 2022 | 64 | 29 | 82.86% | 63 | 1 |
| Dec 31, 2021 | 35 | 13 | 59.09% | 34 | 1 |
| Dec 31, 2020 | 22 | - | - | 20 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 124 |
| Kezar Life Sciences | 55 |
| NextCure | 43 |
| BeyondSpring | 40 |
| MiNK Therapeutics | 23 |
| Lipocine | 16 |
| Nutriband | 13 |
| Spruce Biosciences | 9 |
LONA News
- 19 days ago - LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer - GlobeNewsWire
- 2 months ago - Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition? - Benzinga
- 2 months ago - Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript - Seeking Alpha
- 2 months ago - Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment - GeekWire
- 2 months ago - Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million - GlobeNewsWire
- 5 months ago - Athira Pharma Announces Reverse Stock Split - GlobeNewsWire
- 10 months ago - Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit - GlobeNewsWire
- 10 months ago - Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates - GlobeNewsWire